TY - JOUR
KW - opioid epidemic
KW - opioid use disorder
KW - Opioids
KW - Substance Abuse
AU - S. Kuppalli
AU - R. Seth
AU - V. Orhurhu
AU - I. Urits
AU - A. D. Kaye
AU - C. Hunter
AU - A. Gulati
AU - P. Adekoya
AU - A. M. Kaye
AU - M. R. Jones
A1 - 
AB - PURPOSE OF REVIEW: Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States' healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy. RECENT FINDINGS: Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR), but several pharmacologic, clinical, and practical barriers limit these treatments' market viability. This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD treatment.
AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Southcoast Health, Southcoast Health Physicians Group, Fall River, MA, USA.; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.; Ainsworth Institute of Pain Management, New York, NY, USA.; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Departments of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.; Thomas J. Long School of Pharmacy and Health Sciences, Department of Pharmacy Practice, University of the Pacific, Stockton, CA, USA.; Department of Anesthesiology, Weill Cornell Medical College, New York, NY, USA. mrj9011@NYP.org.
BT - Current pain and headache reports
C5 - Opioids & Substance Use
CP - 4
CY - United States
DO - 10.1007/s11916-021-00941-8
IS - 4
JF - Current pain and headache reports
LA - eng
M1 - Journal Article
N2 - PURPOSE OF REVIEW: Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States' healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy. RECENT FINDINGS: Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR), but several pharmacologic, clinical, and practical barriers limit these treatments' market viability. This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD treatment.
PP - United States
PY - 2021
SN - 1534-3081; 1534-3081
SP - 021
EP - 8
EP - 23+
T1 - Recent Advances in the Treatment of Opioid Use Disorder
T2 - Current pain and headache reports
TI - Recent Advances in the Treatment of Opioid Use Disorder
U1 - Opioids & Substance Use
U2 - 33693999
U3 - 10.1007/s11916-021-00941-8
VL - 25
VO - 1534-3081; 1534-3081
Y1 - 2021
Y2 - Mar 11
ER -